SCHEMBL2362903

SCHEMBL2362903

Cc1ccc(C(c2ccc(C)cc2)C(Cl)(Cl)Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.61
TDP1 Q9NUW8 3/20 0.61
LMNA P02545 3/20 0.61
MAPK1 P28482 2/20 0.61
HPGD P15428 2/20 0.61
TP53 P04637 1/20 0.61
HIF1A Q16665 1/20 0.61
ESR1 P03372 1/20 0.58
ESR2 Q92731 1/20 0.58
ALDH1A1 P00352 5/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
CHRNA7 P36544 1/20 0.42
ACHE P22303 5/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
POLB P06746 1/20 0.33
CYP19A1 P11511 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23930702 0.97 TSHR (0.58) TSHRTDP1LMNAMAPK1HPGD
SCHEMBL12319176 0.91 TSHR (0.78) TSHRTDP1LMNAMAPK1HPGD
SCHEMBL11858640 0.85 ALDH1A1 (0.85) TSHRTDP1LMNAMAPK1HPGD
SCHEMBL11849358 0.81 TSHR (0.55) TSHRTDP1LMNAMAPK1HPGD
SCHEMBL11593534 0.79 CHRNA7 (0.42) TSHRTDP1LMNAMAPK1HPGD
SCHEMBL11289948 0.79 CHRNA7 (0.42) TSHRTDP1LMNAMAPK1HPGD
Chlorophenothane SCHEMBL2065589 0.76 TSHR (1.00) TSHRTDP1LMNAMAPK1HPGD
Chlorophenothane SCHEMBL7181 0.76 TSHR (1.00) TSHRTDP1LMNAMAPK1HPGD
Chlorophenothane SCHEMBL11570317 0.75 TSHR (0.86) TSHRTDP1LMNAMAPK1HPGD
SCHEMBL11302427 0.75 HPGD (0.44) TSHRTDP1LMNAMAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2568807-B1 PHENOXYALKYL PYRIDINIUM OXIME THERAPEUTICS FOR TREATMENT OF ORGANOPHOSPHATE POISONING UNIV MISSISSIPPI STATE (US) 2018-07-11 EP claimed
EP-1381576-B1 A PROCESS FOR COATING A SILICEOUS SUBSTRATE WITH A SILICON CONTAINING LAYER ICT COATINGS N V (BE) 2005-03-23 EP claimed
US-12435377-B2 Cancers with loss of chromosome 16Q and/or low expression of metallothionein proteins THE BROAD INSTITUTE, INC. (US) 2025-10-07 US disclosed
US-20250281509-A1 SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER THE JOHNS HOPKINS UNIVERSTY 2025-09-11 US disclosed
US-20250041316-A1 METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASE UNIV TEMPLE (US) 2025-02-06 US disclosed
CN-115873254-B Silicone resin, preparation method and application 杭州师范大学 2024-02-02 CN disclosed
CN-116986967-A Method for catalyzing carbon monoxide, methanol and methyl nitrite to synthesize dimethoxymethane and dimethyl carbonate in gas phase 中国石油大学(华东) 2023-11-03 CN disclosed
CN-109688807-B Plants with increased herbicide tolerance 巴斯夫欧洲公司 2023-04-28 CN disclosed
EP-3467006-B1 MIXTURES OF CYCLIC BRANCHED D/T-TYPE SILOXANES AND THEIR ENSUING PRODUCTS EVONIK OPERATIONS GMBH (DE) 2022-11-30 EP disclosed
WO-2020114609-A1 PROCESS FOR REDUCING THE CONTENT OF BORON COMPOUNDS IN HALOSILANE-CONTAINING COMPOSITIONS WACKER CHEMIE AG (DE) 2020-06-11 WO disclosed
US-20120107725-A1 Solid Polymer Electrolyte Composition, and Ion-Exchange Membrane, Membrane Electrode Assembly and Fuel Cell TOYO BOSEKI KABUSHIKI KAISHA (JP) 2012-05-03 US disclosed
EP-1144736-B1 AGGLOMERATION OF SILICON POWDERS GE BAYER SILICONES GMBH & CO (DE) 2004-08-25 EP disclosed
EP-1144736-A1 AGGLOMERATION OF SILICON POWDERS GE Bayer Silicones GmbH & Co. KG (DE) 2001-10-17 EP disclosed
WO-2000037719-A1 AGGLOMERATION OF SILICON POWDERS GE BAYER SILICONES GMBH & CO. KG (DE) 2000-06-29 WO disclosed
EP-0372341-A3 METHOD FOR THE PREPARATION OF CHLORO-ORGANOSILANES BAYER AG (DE) 1991-03-27 EP disclosed
EP-0372341-A2 Method for the preparation of chloro-organosilanes BAYER AG (DE) 1990-06-13 EP disclosed
EP-0305019-A1 Process for the destruction of chemical waste materials, in particular of organic halogen compounds, by hydrogenolysis Rijksuniversiteit Leiden (NL) 1989-03-01 EP disclosed
EP-0269833-A2 Silicon-containing polyamide compositions BAYER AG (DE) 1988-06-08 EP disclosed
US-3966824-A BIODEGRADABLE INSECTICIDES UNIVERSITY OF ILLINOIS FOUNDATION (US) 1976-06-29 US disclosed
US-3941842-A INSECTICIDE, LARVICIDE THE UNIVERSITY OF ILLINOIS FOUNDATION (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250041316-A1 METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASE LIPC, GYS2, FABP1 TSHR 2840/4885TDP1 4811/4885LMNA 1042/4885
US-12435377-B2 Cancers with loss of chromosome 16Q and/or low expression of metallothionein proteins GSTM2, GSTM1, AS3MT TSHR 1484/4885TDP1 2079/4885LMNA 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.